Literature DB >> 30138677

Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.

Ying Luo1, Yu Xia1, Wenjing Wang2, Zhichuan Li3, Yan Jin4, Yifeng Gong4, Tingyan He1, Qiu Li5, Chengrong Li6, Jun Yang7.   

Abstract

Activated phosphoinositide 3-kinase δ (PI3Kδ) syndrome is a newly defined and relatively common primary immunodeficiency, which is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1. Here, we report a novel de novo GOF mutation (c.1570 T > A, p.Y524N) in PIK3CD in a 6-year-old Chinese girl. The patient suffered recurrent sinopulmonary infection, bronchiectasis, lymphoproliferation, herpesvirus infection, and distinctive nodular lymphoid hyperplasia of mucosal surfaces. Immunological analysis revealed increased CD4+ T cell senescence and B cell immaturity. Further analysis revealed an increase in almost all CD4+ T cell subsets to varying degrees, including effector T cells and Treg cells. Increased levels of plasma T cell-related cytokines corroborated these results. Hyperactivation of the PI3Kδ-Akt-mTOR signaling pathway was also confirmed. Treatment with rapamycin ameliorated the lymphoproliferative immunodeficiency caused by hyperactivation of mTOR. These results expand genetic spectrum of APDS and will facilitate further study of the genotype-phenotype correlation in those with PIK3CD mutations.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Activated phosphoinositide 3-kinase δ syndrome; Immunodeficiency; Lymphoproliferation; PIK3CD

Mesh:

Substances:

Year:  2018        PMID: 30138677     DOI: 10.1016/j.clim.2018.08.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  4 in total

1.  Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.

Authors:  Ying Wang; Wenjie Wang; Luyao Liu; Jia Hou; Wenjing Ying; Xiaoying Hui; Qinhua Zhou; Danru Liu; Haili Yao; Jinqiao Sun; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2018-11-29       Impact factor: 8.542

2.  Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene.

Authors:  Wenjie Wang; Qing Min; Nannan Lai; Krisztian Csomos; Ying Wang; Luyao Liu; Xin Meng; Jinqiao Sun; Jia Hou; Wenjing Ying; Qinhua Zhou; Bijun Sun; Xiaoying Hui; Boglarka Ujhazi; Sumai Gordon; David Buchbinder; Catharina Schuetz; Manish Butte; Jolan E Walter; Xiaochuan Wang; Ji-Yang Wang
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

3.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

Review 4.  Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.

Authors:  Romane Thouenon; Nidia Moreno-Corona; Lucie Poggi; Anne Durandy; Sven Kracker
Journal:  Front Pediatr       Date:  2021-06-25       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.